Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting
المؤلفون المشاركون
Ye, Ming
Wu, Bin
Lu, Jingsong
Yang, Fan
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-08-02
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Objective.
Long-term aromatase inhibitor (AI) therapy is expected to improve the health outcomes with high health resource consumption in early breast cancer.
The aim of the study was to assess the cost-effectiveness of letrozole for postmenopausal women with estrogen receptor positive early breast cancer in a health resource-limited setting.
Methods.
A Markov model was developed to project the lifetime outcomes based on the clinical course of early breast cancer.
The clinical and utility data were derived from reported results.
Costs were estimated from the perspective of Chinese health care.
The quality-adjusted life-year (QALY) and incremental cost-effective ratio (ICER) were measured.
Probabilistic sensitivity and one-way analyses were conducted.
Results.
Compared to 5 years of tamoxifen therapy, 5 years of AI treatment with letrozole improved the QALYs (10.44 versus 10.84) and increased the lifetime costs (CNY ¥13,613 versus CNY ¥28,797), resulting in an ICER of CNY ¥38,092 /QALY.
The ICER of 5 years of letrozole versus 2–3 years of tamoxifen and then letrozole was CNY ¥68,233 /QALY.
Sensitivity analyses showed that the age of initiating adjuvant endocrine therapy was the most influential parameter.
Conclusions.
In health resource-limited settings, adjuvant endocrine therapy with letrozole is a cost-effective strategy compared to tamoxifen in women with early breast cancer.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ye, Ming& Lu, Jingsong& Yang, Fan& Wu, Bin. 2018. Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting. BioMed Research International،Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1129651
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ye, Ming…[et al.]. Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting. BioMed Research International No. 2018 (2018), pp.1-8.
https://search.emarefa.net/detail/BIM-1129651
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ye, Ming& Lu, Jingsong& Yang, Fan& Wu, Bin. Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-8.
https://search.emarefa.net/detail/BIM-1129651
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1129651
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر